FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 03/2022”.
The Monitor is a month-to-month revealed overview of enterprise capital tendencies within the US-Biotech sector.
As of the tip of March 2022, we determine the next present VC tendencies within the US-Biotech sector:
- In 2022, total Biotech funding within the USA has reached USD 9,341m to date
- High 5 offers exceed USD 180m every, largest transaction amounted to USD 3,000m in Altos Labs
- Catalio Capital Administration (USA) leads the High 5 Buyers (by deal quantity), adopted by RA Capital Administration (USA) and Vida Ventures (USA)
- Central Nervous System dominates as the highest indication
To entry the complete report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink